Literature DB >> 23324623

Activation of NK cells by HIV-specific ADCC antibodies: role for granulocytes in expressing HIV-1 peptide epitopes.

Vijaya Madhavi1, Marjon Navis, Amy W Chung, Gamze Isitman, Leia H Wren, Robert De Rose, Stephen J Kent, Ivan Stratov.   

Abstract

HIV-specific ADCC antibodies could play a role in providing protective immunity. We have developed a whole blood ADCC assay that measures NK cell activation in response to HIV peptide epitopes. These HIV peptide-specific ADCC responses are associated with escape from immune recognition and slower progression of HIV infection and represent interesting HIV vaccine antigens. However, the mechanism by which these epitopes are expressed and whether or not they induce NK-mediated killing of cells expressing such peptide-antigens is not understood. Herein, we show that fluorescent-tagged ADCC peptide epitopes associate with blood granulocytes. The peptide-associated granulocytes become a specific target for antibody-mediated killing, as shown by enhanced expression of apoptosis marker Annexin and reduction in cell numbers. When HIV Envelope gp140 protein is utilized in the ADCC assay, we detected binding to its ligand, CD4. During the incubation, cells co-expressing gp140 and CD4 reduce in number. We also detected increasing Annexin expression in these cells. These data indicate that blood cells expressing HIV-specific ADCC epitopes are targeted for killing by NK cells in the presence of ADCC antibodies in HIV+ plasma and provide a clearer framework to evaluate these antigens as vaccine candidates.

Entities:  

Keywords:  ADCC; Apoptosis; Granulocytes; HIV; NK cells

Mesh:

Substances:

Year:  2013        PMID: 23324623      PMCID: PMC3899135          DOI: 10.4161/hv.23446

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  36 in total

Review 1.  HIV disease-related neutropenia: an independent risk factor for severe infections.

Authors:  P Hermans
Journal:  AIDS       Date:  1999       Impact factor: 4.177

2.  Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells.

Authors:  D N Forthal; G Landucci; E S Daar
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

3.  Polymorphonuclear neutrophils pulsed with synthetic peptides efficiently activate memory cytotoxic T lymphocytes.

Authors:  E Reali; R Guerrini; S Moretti; S Spisani; F Lanza; R Tomatis; S Traniello; R Gavioli
Journal:  J Leukoc Biol       Date:  1996-08       Impact factor: 4.962

4.  Lack of cross-reaction in antibody-dependent cellular cytotoxicity between human immunodeficiency virus (HIV) and HIV-related West African strains.

Authors:  K Ljunggren; F Chiodi; G Biberfeld; E Norrby; M Jondal; E M Fenyö
Journal:  J Immunol       Date:  1988-01-15       Impact factor: 5.422

5.  Activation of NK cells by ADCC antibodies and HIV disease progression.

Authors:  Amy W Chung; Marjon Navis; Gamze Isitman; Leia Wren; Julie Silvers; Janaki Amin; Stephen J Kent; Ivan Stratov
Journal:  J Acquir Immune Defic Syndr       Date:  2011-10-01       Impact factor: 3.731

Review 6.  Neutropenia, neutrophil dysfunction, and bacterial infection in patients with human immunodeficiency virus disease: the role of granulocyte colony-stimulating factor.

Authors:  D R Kuritzkes
Journal:  Clin Infect Dis       Date:  2000-02       Impact factor: 9.079

Review 7.  Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure.

Authors:  M van Engeland; L J Nieland; F C Ramaekers; B Schutte; C P Reutelingsperger
Journal:  Cytometry       Date:  1998-01-01

8.  A bispecific antibody composed of a nonneutralizing antibody to the gp41 immunodominant region and an anti-CD89 antibody directs broad human immunodeficiency virus destruction by neutrophils.

Authors:  Mark Duval; Marshall R Posner; Lisa A Cavacini
Journal:  J Virol       Date:  2008-02-13       Impact factor: 5.103

9.  Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines.

Authors:  Ruth H Florese; Thorsten Demberg; Peng Xiao; LaRene Kuller; Kay Larsen; L Ebonita Summers; David Venzon; Aurelio Cafaro; Barbara Ensoli; Marjorie Robert-Guroff
Journal:  J Immunol       Date:  2009-03-15       Impact factor: 5.422

10.  Increased neutrophil apoptosis in chronically SIV-infected macaques.

Authors:  Carole Elbim; Valérie Monceaux; Stéphanie François; Bruno Hurtrel; Marie-Anne Gougerot-Pocidalo; Jérome Estaquier
Journal:  Retrovirology       Date:  2009-03-24       Impact factor: 4.602

View more
  5 in total

1.  Slaying the Trojan horse: natural killer cells exhibit robust anti-HIV-1 antibody-dependent activation and cytolysis against allogeneic T cells.

Authors:  Shayarana L Gooneratne; Jonathan Richard; Wen Shi Lee; Andrés Finzi; Stephen J Kent; Matthew S Parsons
Journal:  J Virol       Date:  2014-10-15       Impact factor: 5.103

Review 2.  Natural killer cells in HIV-1 infection and therapy.

Authors:  Joanna Mikulak; Ferdinando Oriolo; Elisa Zaghi; Clara Di Vito; Domenico Mavilio
Journal:  AIDS       Date:  2017-11-13       Impact factor: 4.177

3.  Monoclonal Antibody 2C6 Targets a Cross-Clade Conformational Epitope in gp41 with Highly Active Antibody-Dependent Cell Cytotoxicity.

Authors:  Hakimuddin Sojar; Sarah Baron; Jonathan T Sullivan; Meghan Garrett; Marlies M van Haaren; Jonathon Hoffman; Julie Overbaugh; Benjamin J Doranz; Mark D Hicar
Journal:  J Virol       Date:  2019-08-13       Impact factor: 5.103

4.  Antibody-dependent CD56+ T cell responses are functionally impaired in long-term HIV-1 infection.

Authors:  Xueying Fan; Liyan Zhu; Hua Liang; Zhe Xie; Xiangbo Huang; Shuo Wang; Tao Shen
Journal:  Retrovirology       Date:  2016-11-04       Impact factor: 4.602

Review 5.  Influenza A Virus Antibodies with Antibody-Dependent Cellular Cytotoxicity Function.

Authors:  Rongyuan Gao; Zizhang Sheng; Chithra C Sreenivasan; Dan Wang; Feng Li
Journal:  Viruses       Date:  2020-03-01       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.